Quotient Clinical, a strong performer in last year's Catalyst Pharma Fast 50, has announced yet another acquisition. Acquiring Reading-based CDMO Pharmaterials strengthens Quotient’s service portfolio from preclinical formulation development through to commercial manufacturing, expanding their global CDMO services with added capacity and capabilities. The excitement doesn't stop there though as they have also unveiled their new identity as Quotient Sciences.